Home Tags Abingworth

Abingworth

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was led by new investors Mubadala Capital and Exor Ventures, with participation from Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners.

[Funding News] Iambic Therapeutics Raises $50 Mn Series B Extension Funding

Team SR -
© Copyright startuprise 2024 All Rights Reserved.